EVI1 gene
Wang W, Cortes JE, Lin P, Beaty MW, Ai D, Amin HA, McDonenell TJ, Ok CY, Kantarjian HM, Medeiros LJ & Hu S. Clinical and prognostic significance of 3q26.2 rearrangements and other chromosome 3 abnormalities in CML in the era of tyrosine kinase inhibitors. Blood. 2015 Oct 1;126(14):1699-706. doi: 10.1182/blood-2015- 05-646489.
Highlighted by MDedge Hematology News: Chromosome 3 abnormalities linked to poor CML outcomes
Highlighted by News Medical: Chromosome 3q26.2 rearrangements linked to poor CML prognosis
Wang W, Cortes JE, Tang G, Khoury JD, Wang S, Bueso-Ramos CE, DiGiuseppe JA, Chen Z, Kantarjian KM, Medeiros LJ, Hu S. Risk stratification of chromosomal abnormalities in chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy. Blood. 2016 Jun 2;127(22):2742-2750. doi: 10.1182/blood-2016-01-690230. PMID: 27006386
Chen Z, Chen S, Wang W, Zuo Z, Mou X, Hu SJ, DiGiuseppe JA, Zu Y, Medeiros LJ & Hu S. Cytogenetic landscape and impact in blast phase of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy. Leukemia. 2017 Mar:31(3):585-592. doi: 10.1038/leu.2016.231
Faculty spotlight by MD Anderson Cancer Center
Highlighted by iCMLf in Latest advances from key CML publications: ACAs characterised for blast phase–CML after TKI therapy
Chen Z, Cortes JE, Jorgensen JL, Wang W, Yin CC, You MJ, Jabbour E, Kantarjian HM, Medeiros LJ, Hu S. Differential impact of additional chromosomal abnormalities in myeloid vs lymphoid blast phase of chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy. Leukemia. 2016 Jul;30(7):1606-1609. doi: 10.1038/leu.2016.6. PMID: 26837843
Gong Z, Medeiros LJ, Cortes JE, Chen Z, Zheng L, Li Y, Bai S, Lin P, Miranda RN, Jorgensen LJ, McDonnell TJ, Wang W, Kantarjian H, Hu S. Cytogenetics-based risk prediction of blastic transformation of CML treated with tyrosine kinase inhibitors. Blood Adv. 2017 Dec 12;1(26):2541-2552
Highlighted by NCCN: Chromosomal Alterations in Predicting Blastic Transformation in CML
Hu Z, Medeiros LJ, Wang W, Chen Z, Tang G, Hodjat P, Yang S, Fang L, Li Y, Verstovsek S, Hu S. 3q26.2 rearrangement is associated with poor prognosis in Ph-negative myeloproliferative neoplasm. Mod Pathol. 2017 Jul;30(7):940-951. doi: 10.1038/modpathol.2017.19. PMID: 28338652
Ronaghy A, Hu S, Tang Z, Wang W, Tang G, Lohgavi S, Li S. Thakral B, Medeiros LJ, Muzzafar T. Myeloid neoplasms associated with t(3;12)(p26.2;p13) are clinical aggressive, show myelodysplasia, and frequently harbor chromosome 7 abnormalities. Mod Pathol. 2021 Feb;34(2):300-313. doi: 10.1038/s41379-020-00663-z. PMID: 33110238.
Gong Z, Wang W, Hu S. Cytogenetics alterations in CML: not all created equal. Oncotarget 2018 Feb 10;9(15):11885-11886. doi: 10.18632/oncotarget.24471. PMID: 29552278
Zhou T, Medeiros LJ, Hu S. Chronic myeloid leukemia: beyond BCR-ABL1. Curr Hematol Malig Rep. 2018 Dec;13(6):435-445. doi: 10.1007/s11899-018-0474-6. PMID: 30370478
Hu Z, Hu S, Ji C, Tang Z, Thakral B, Loghavi S, Medeiros LJ, Wang W. 3q26.2/EVI1 rearrangement in myelodysplastic/myeloproliferative neoplasms: an early event associated with a poor prognosis. Leuk Res. 2018 Feb;65:25-28. doi: 10.1016/j.leukres.2017.12.004. PMID: 29288910
Tang G, Hu S, Wang SA, Xie W, Lin P, Xu J, Toruner G, Zhao M, Gu J, Doty M, Li S, Medeiros LJ, Tang Z. t(3;8)(q26.2;q24) often leads to MECOM/MYC rearrangement and is commonly associated with therapy-related myeloid neoplasms and/or disease progression. J Mol Diagn. 2019 Mar;21(2):343-351. doi: 10.1016/j.jmoldx.2018.10.005. PMID: 30576868
Tang Z, Tang G, Hu S, Patel KP, Yin CC, Wang W, Lin P, Toruner GA, OK CY, Gu J, Lu X, Khoury JD, Medeiros LJ. Deciphering the complexities of MECOM rearrangement in myeloid malignancies. Cancer Genet. 2019 Mar;21(2):343-351. doi: 10.1016/j.cancergen.2019.03.002. PMID: 31109591
Zhao M, Medeiros LJ, Wang W, Tang G, Jung SK, Sfamenos SM, Fang H, Torunner GA, Hu S, Yin CC, Lin P, Gu J, Peng G, You MJ, Khoury JD, Wang SA, Tang Z. Newly designed breakapart FISH probe helps to identify cases with true MECOM rearrangement in myeloid malignancies. Cancer Genet. 2022 Apr;262-263:23-29. doi: 10.1016/j.cancergen.2021.12.009. PMID: 34974290.
Highlighted by MDedge Hematology News: Chromosome 3 abnormalities linked to poor CML outcomes
Highlighted by News Medical: Chromosome 3q26.2 rearrangements linked to poor CML prognosis
Wang W, Cortes JE, Tang G, Khoury JD, Wang S, Bueso-Ramos CE, DiGiuseppe JA, Chen Z, Kantarjian KM, Medeiros LJ, Hu S. Risk stratification of chromosomal abnormalities in chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy. Blood. 2016 Jun 2;127(22):2742-2750. doi: 10.1182/blood-2016-01-690230. PMID: 27006386
Chen Z, Chen S, Wang W, Zuo Z, Mou X, Hu SJ, DiGiuseppe JA, Zu Y, Medeiros LJ & Hu S. Cytogenetic landscape and impact in blast phase of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy. Leukemia. 2017 Mar:31(3):585-592. doi: 10.1038/leu.2016.231
Faculty spotlight by MD Anderson Cancer Center
Highlighted by iCMLf in Latest advances from key CML publications: ACAs characterised for blast phase–CML after TKI therapy
Chen Z, Cortes JE, Jorgensen JL, Wang W, Yin CC, You MJ, Jabbour E, Kantarjian HM, Medeiros LJ, Hu S. Differential impact of additional chromosomal abnormalities in myeloid vs lymphoid blast phase of chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy. Leukemia. 2016 Jul;30(7):1606-1609. doi: 10.1038/leu.2016.6. PMID: 26837843
Gong Z, Medeiros LJ, Cortes JE, Chen Z, Zheng L, Li Y, Bai S, Lin P, Miranda RN, Jorgensen LJ, McDonnell TJ, Wang W, Kantarjian H, Hu S. Cytogenetics-based risk prediction of blastic transformation of CML treated with tyrosine kinase inhibitors. Blood Adv. 2017 Dec 12;1(26):2541-2552
Highlighted by NCCN: Chromosomal Alterations in Predicting Blastic Transformation in CML
Hu Z, Medeiros LJ, Wang W, Chen Z, Tang G, Hodjat P, Yang S, Fang L, Li Y, Verstovsek S, Hu S. 3q26.2 rearrangement is associated with poor prognosis in Ph-negative myeloproliferative neoplasm. Mod Pathol. 2017 Jul;30(7):940-951. doi: 10.1038/modpathol.2017.19. PMID: 28338652
Ronaghy A, Hu S, Tang Z, Wang W, Tang G, Lohgavi S, Li S. Thakral B, Medeiros LJ, Muzzafar T. Myeloid neoplasms associated with t(3;12)(p26.2;p13) are clinical aggressive, show myelodysplasia, and frequently harbor chromosome 7 abnormalities. Mod Pathol. 2021 Feb;34(2):300-313. doi: 10.1038/s41379-020-00663-z. PMID: 33110238.
Gong Z, Wang W, Hu S. Cytogenetics alterations in CML: not all created equal. Oncotarget 2018 Feb 10;9(15):11885-11886. doi: 10.18632/oncotarget.24471. PMID: 29552278
Zhou T, Medeiros LJ, Hu S. Chronic myeloid leukemia: beyond BCR-ABL1. Curr Hematol Malig Rep. 2018 Dec;13(6):435-445. doi: 10.1007/s11899-018-0474-6. PMID: 30370478
Hu Z, Hu S, Ji C, Tang Z, Thakral B, Loghavi S, Medeiros LJ, Wang W. 3q26.2/EVI1 rearrangement in myelodysplastic/myeloproliferative neoplasms: an early event associated with a poor prognosis. Leuk Res. 2018 Feb;65:25-28. doi: 10.1016/j.leukres.2017.12.004. PMID: 29288910
Tang G, Hu S, Wang SA, Xie W, Lin P, Xu J, Toruner G, Zhao M, Gu J, Doty M, Li S, Medeiros LJ, Tang Z. t(3;8)(q26.2;q24) often leads to MECOM/MYC rearrangement and is commonly associated with therapy-related myeloid neoplasms and/or disease progression. J Mol Diagn. 2019 Mar;21(2):343-351. doi: 10.1016/j.jmoldx.2018.10.005. PMID: 30576868
Tang Z, Tang G, Hu S, Patel KP, Yin CC, Wang W, Lin P, Toruner GA, OK CY, Gu J, Lu X, Khoury JD, Medeiros LJ. Deciphering the complexities of MECOM rearrangement in myeloid malignancies. Cancer Genet. 2019 Mar;21(2):343-351. doi: 10.1016/j.cancergen.2019.03.002. PMID: 31109591
Zhao M, Medeiros LJ, Wang W, Tang G, Jung SK, Sfamenos SM, Fang H, Torunner GA, Hu S, Yin CC, Lin P, Gu J, Peng G, You MJ, Khoury JD, Wang SA, Tang Z. Newly designed breakapart FISH probe helps to identify cases with true MECOM rearrangement in myeloid malignancies. Cancer Genet. 2022 Apr;262-263:23-29. doi: 10.1016/j.cancergen.2021.12.009. PMID: 34974290.